Skip to main content
. Author manuscript; available in PMC: 2020 May 13.
Published in final edited form as: J Clin Lipidol. 2019 Apr 3;13(3):481–491.e1. doi: 10.1016/j.jacl.2019.03.005

Figure 2.

Figure 2.

Baseline Lactosyl-Sphingolipids associations with kidney dysfunction outcomes.

Data are shown as hazard ratios (95% CI) adjusted for DCCT treatment assignment, baseline retinopathy cohort, gender, baseline levels of eGFR, AER, HbA1c %, LDL cholesterol, triglycerides, systolic blood pressure, age, and a variable indicating the use of ACE/ARB drugs prior to disease progression of censoring of subject study data. Total lactosyl species levels calculated as the sum of each measured lactosyl species level. P<0.05